Skip to search formSkip to main contentSkip to account menu

AZD6738

Known as: ATR Kinase Inhibitor AZD6738, AZD-6738 
An orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

3 relations
NCIt Antineoplastic Agent Terminology

Broader (2)

PyrimidinesSulfoxides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
Background Radioimmunotherapy has a promising antitumor effect in hepatocellular carcinoma (HCC), depending on the regulatory… 
Highly Cited
2019
Highly Cited
2019
ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment
Purpose: ATR inhibitors (ATRi) are in early phase clinical trials and have been shown to sensitize to chemotherapy and… 
Highly Cited
2018
Highly Cited
2018
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation
DNA-damaging chemotherapy and radiation therapy are integrated into the treatment paradigm of the majority of cancer patients… 
Highly Cited
2018
Highly Cited
2018
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.
The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical… 
Highly Cited
2018
Highly Cited
2018
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, and overall survival rates have barely improved over the… 
Highly Cited
2018
Highly Cited
2018
Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
2017
2017
Anti‐tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells
Ataxia telangiectasia and Rad3‐related (ATR) proteins are sensors of DNA damage, which induces homologous recombination (HR… 
Highly Cited
2016
Highly Cited
2016
Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei
AZD6738 is an orally active ATR inhibitor (ATRi) currently in phase I clinical trials. We found in vitro growth inhibitory… 
2015
2015
Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
Understanding the therapeutic effect of drug dose and scheduling is critical to inform the design and implementation of clinical… 
Review
2015
Review
2015
Molecular Pathways: Targeting ATR in Cancer Therapy
The human ATR gene encodes a kinase that is activated by DNA damage and replication stress as a central transducer of a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)